CPI-0610, CPI-0610
CDAK539A12001B
Phase 3 small_molecule active
Quick answer
CPI-0610, CPI-0610 for Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia) is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active